Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.24
PKI's Cash to Debt is ranked higher than
51% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. PKI: 0.24 )
PKI' s 10-Year Cash to Debt Range
Min: 0.09   Max: 2.06
Current: 0.24

0.09
2.06
Equity to Asset 0.53
PKI's Equity to Asset is ranked higher than
66% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. PKI: 0.53 )
PKI' s 10-Year Equity to Asset Range
Min: 0.24   Max: 0.63
Current: 0.53

0.24
0.63
Interest Coverage 4.36
PKI's Interest Coverage is ranked higher than
51% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. PKI: 4.36 )
PKI' s 10-Year Interest Coverage Range
Min: 2.15   Max: 16.75
Current: 4.36

2.15
16.75
F-Score: 8
Z-Score: 3.21
M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.73
PKI's Operating margin (%) is ranked higher than
88% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. PKI: 11.73 )
PKI' s 10-Year Operating margin (%) Range
Min: 1.62   Max: 10.86
Current: 11.73

1.62
10.86
Net-margin (%) 8.69
PKI's Net-margin (%) is ranked higher than
87% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. PKI: 8.69 )
PKI' s 10-Year Net-margin (%) Range
Min: -10.1   Max: 22.94
Current: 8.69

-10.1
22.94
ROE (%) 9.63
PKI's ROE (%) is ranked higher than
83% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. PKI: 9.63 )
PKI' s 10-Year ROE (%) Range
Min: -11.62   Max: 32.47
Current: 9.63

-11.62
32.47
ROA (%) 4.95
PKI's ROA (%) is ranked higher than
83% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. PKI: 4.95 )
PKI' s 10-Year ROA (%) Range
Min: -5.23   Max: 12.48
Current: 4.95

-5.23
12.48
ROC (Joel Greenblatt) (%) 57.06
PKI's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. PKI: 57.06 )
PKI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.35   Max: 69.55
Current: 57.06

4.35
69.55
Revenue Growth (3Y)(%) 9.70
PKI's Revenue Growth (3Y)(%) is ranked higher than
81% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. PKI: 9.70 )
PKI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.3   Max: 17.9
Current: 9.7

-12.3
17.9
EBITDA Growth (3Y)(%) 8.30
PKI's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. PKI: 8.30 )
PKI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.9   Max: 35.2
Current: 8.3

-20.9
35.2
EPS Growth (3Y)(%) 7.80
PKI's EPS Growth (3Y)(%) is ranked higher than
80% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. PKI: 7.80 )
PKI' s 10-Year EPS Growth (3Y)(%) Range
Min: -79   Max: 289.3
Current: 7.8

-79
289.3
» PKI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PKI Guru Trades in Q4 2013

Jim Simons 172,600 sh (+177.49%)
PRIMECAP Management 1,733,244 sh (+11.54%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Columbia Wanger 972,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 3,577,620 sh (-0.42%)
Ken Fisher 616,535 sh (-6.13%)
» More
Q1 2014

PKI Guru Trades in Q1 2014

Steven Cohen 23,795 sh (New)
RS Investment Management 489,954 sh (New)
Jim Simons 322,000 sh (+86.56%)
PRIMECAP Management 2,116,074 sh (+22.09%)
Columbia Wanger 972,000 sh (unchged)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Chuck Royce 3,540,320 sh (-1.04%)
Ken Fisher 609,140 sh (-1.2%)
» More
Q2 2014

PKI Guru Trades in Q2 2014

Joel Greenblatt 55,177 sh (New)
PRIMECAP Management 2,116,374 sh (+0.01%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Chuck Royce 3,540,320 sh (unchged)
Columbia Wanger 972,000 sh (unchged)
Ken Fisher 607,924 sh (-0.2%)
RS Investment Management 393,864 sh (-19.61%)
Jim Simons 170,800 sh (-46.96%)
» More
Q3 2014

PKI Guru Trades in Q3 2014

Joel Greenblatt 137,475 sh (+149.15%)
PRIMECAP Management 2,254,111 sh (+6.51%)
Ken Fisher 614,529 sh (+1.09%)
Chuck Royce 3,540,320 sh (unchged)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Columbia Wanger Sold Out
Jim Simons Sold Out
RS Investment Management 393,514 sh (-0.09%)
» More
» Details

Insider Trades

Latest Guru Trades with PKI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 149.15%0.04%$43.51 - $48.25 $ 43.77-4%137475
Joel Greenblatt 2014-06-30 New Buy0.03%$41.97 - $47.52 $ 43.77-2%55177
PRIMECAP Management 2014-03-31 Add 22.09%0.02%$40.94 - $46.21 $ 43.770%2116074
PRIMECAP Management 2013-09-30 Add 23.16%0.01%$32.39 - $38.63 $ 43.7722%1553900
Vanguard Health Care Fund 2013-06-30 New Buy0.17%$30.35 - $34.95 $ 43.7734%1441400
Meridian Funds 2013-06-30 Add 20.08%0.15%$30.35 - $34.95 $ 43.7734%759500
Ken Fisher 2013-06-30 Add 104.07%0.03%$30.35 - $34.95 $ 43.7734%638685
Ray Dalio 2013-06-30 Sold Out 0.02%$30.35 - $34.95 $ 43.7734%0
David Dreman 2013-03-31 Sold Out 0.8%$31.74 - $35.86 $ 43.7728%0
Meridian Funds 2013-03-31 New Buy0.78%$31.74 - $35.86 $ 43.7728%632500
Ray Dalio 2013-03-31 New Buy0.02%$31.74 - $35.86 $ 43.7728%51497
Ken Fisher 2013-03-31 Add 335.3%0.02%$31.74 - $35.86 $ 43.7728%312980
PRIMECAP Management 2012-12-31 Add 28.06%0.01%$27.84 - $32.29 $ 43.7743%1208106
Mario Gabelli 2012-12-31 Sold Out 0.004%$27.84 - $32.29 $ 43.7743%0
PRIMECAP Management 2012-09-30 Add 56.14%0.02%$23.88 - $30.36 $ 43.7762%943359
Joel Greenblatt 2012-06-30 Sold Out 0.09%$24.96 - $27.9 $ 43.7766%0
Ken Fisher 2012-06-30 Add 60.85%$24.96 - $27.9 $ 43.7766%71900
Joel Greenblatt 2012-03-31 Reduce -41.22%0.06%$20.37 - $27.85 $ 43.7783%37369
PRIMECAP Management 2012-03-31 Add 241.19%0.01%$20.37 - $27.85 $ 43.7783%515906
Ken Fisher 2012-03-31 New Buy$20.37 - $27.85 $ 43.7783%44700
David Dreman 2011-12-31 Add 251.88%0.49%$17.49 - $21.61 $ 43.77129%1525635
Ray Dalio 2011-12-31 Sold Out 0.06%$17.49 - $21.61 $ 43.77129%0
PRIMECAP Management 2011-12-31 Add 53.51%$17.49 - $21.61 $ 43.77129%151206
David Dreman 2011-09-30 New Buy0.21%$18.84 - $27.55 $ 43.7791%433571
Ray Dalio 2011-09-30 New Buy0.06%$18.84 - $27.55 $ 43.7791%212908
PRIMECAP Management 2011-09-30 New Buy$18.84 - $27.55 $ 43.7791%98500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.80
PKI's P/E(ttm) is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 25.80 )
PKI' s 10-Year P/E(ttm) Range
Min: 5.27   Max: 3956.25
Current: 25.8

5.27
3956.25
P/B 2.40
PKI's P/B is ranked higher than
84% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. PKI: 2.40 )
PKI' s 10-Year P/B Range
Min: 0.88   Max: 2.65
Current: 2.4

0.88
2.65
P/S 2.23
PKI's P/S is ranked higher than
79% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. PKI: 2.23 )
PKI' s 10-Year P/S Range
Min: 0.72   Max: 2.48
Current: 2.23

0.72
2.48
PFCF 21.99
PKI's PFCF is ranked higher than
91% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 21.99 )
PKI' s 10-Year PFCF Range
Min: 7.78   Max: 92.3
Current: 21.99

7.78
92.3
EV-to-EBIT 21.45
PKI's EV-to-EBIT is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 21.45 )
PKI' s 10-Year EV-to-EBIT Range
Min: 9.4   Max: 57.1
Current: 21.45

9.4
57.1
PEG 2.81
PKI's PEG is ranked higher than
91% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 2.81 )
PKI' s 10-Year PEG Range
Min: 0.58   Max: 46.41
Current: 2.81

0.58
46.41
Shiller P/E 33.04
PKI's Shiller P/E is ranked higher than
93% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 33.04 )
PKI' s 10-Year Shiller P/E Range
Min: 10.11   Max: 41.14
Current: 33.04

10.11
41.14
Current Ratio 1.89
PKI's Current Ratio is ranked higher than
62% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. PKI: 1.89 )
PKI' s 10-Year Current Ratio Range
Min: 0.74   Max: 2.13
Current: 1.89

0.74
2.13
Quick Ratio 1.40
PKI's Quick Ratio is ranked higher than
61% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PKI: 1.40 )
PKI' s 10-Year Quick Ratio Range
Min: 0.54   Max: 1.7
Current: 1.4

0.54
1.7

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.64
PKI's Dividend Yield is ranked lower than
71% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.31 vs. PKI: 0.64 )
PKI' s 10-Year Dividend Yield Range
Min: 0.58   Max: 2.43
Current: 0.64

0.58
2.43
Dividend Payout 0.16
PKI's Dividend Payout is ranked higher than
97% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 0.16 )
PKI' s 10-Year Dividend Payout Range
Min: 0.03   Max: 3.5
Current: 0.16

0.03
3.5
Yield on cost (5-Year) 0.70
PKI's Yield on cost (5-Year) is ranked lower than
74% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. PKI: 0.70 )
PKI' s 10-Year Yield on cost (5-Year) Range
Min: 0.58   Max: 2.43
Current: 0.7

0.58
2.43
Share Buyback Rate 1.30
PKI's Share Buyback Rate is ranked higher than
93% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. PKI: 1.30 )
PKI' s 10-Year Share Buyback Rate Range
Min: 6.7   Max: -11.2
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.55
PKI's Price/DCF (Projected) is ranked higher than
93% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 1.55 )
PKI' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 131.1
Current: 1.55

0.52
131.1
Price/Median PS Value 1.28
PKI's Price/Median PS Value is ranked higher than
73% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. PKI: 1.28 )
PKI' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.94
Current: 1.28

0.23
1.94
Price/Peter Lynch Fair Value 1.58
PKI's Price/Peter Lynch Fair Value is ranked higher than
95% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PKI: 1.58 )
PKI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.74   Max: 16.36
Current: 1.58

0.74
16.36
Earnings Yield (Greenblatt) 4.70
PKI's Earnings Yield (Greenblatt) is ranked higher than
87% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. PKI: 4.70 )
PKI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 10.6
Current: 4.7

1.8
10.6
Forward Rate of Return (Yacktman) 19.04
PKI's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. PKI: 19.04 )
PKI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -20.7   Max: 43.7
Current: 19.04

-20.7
43.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:PKN.Germany,
PerkinElmer Inc is a Massachusetts corporation, founded in 1947. The Company provides products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its advanced technologies, solutions, and services, it addresses critical issues that help to improve the health and safety of people and their environment. The Company reports its business in two segments: Human Health and Environmental Health. Its Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, it serves both the Diagnostics and Research Markets. In Diagnostics Markets it provides early detection for genetic disorders from pre-conception to early childhood, as well as digital x-ray flat panel detectors and infectious disease testing for the diagnostics market. In the Research market, it provides suite of solutions including reagents, liquid handling and detection and imaging technologies that enable researchers to improve the drug discovery process. Its main products for Human Health applications includes DELFIA Xpress screening platform, NeoGram MS/MS AAAC in vitro diagnostic kit, NeoBase Non-derivatized MS/MS kit, Specimen Gate informatics data management solution, XRD family of amorphous silicon digital x-ray flat panel detectors, Opera high content screening system and Operetta high content imaging system, UltraVIEW VoX 3D live cell imaging system and Asset Genius, an informatics-based business intelligence solution. Its Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. Its main products Environmental Health applications includes Clarus series of gas chromatographs, Flexar series of liquid chromatography and mass spectrometry instruments and LAMBDA UV/Vis series. The Company's main brands include AlphaLISA, AlphaScreen, Asset Genius, AutoDELFIA, BACS-on-Beads, BoBs, cell::explorer, Chem3D, ChemBioOffice, ChemDraw, Columbus, Datalytix, Dexela CMOS FPDs, Elsevier's Reaxys, EnLite, Ensemble for Biology, Ensemble for Chemistry and Ensemble for QA/QC. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors and government agencies. It competes with foreign and domestic organizations, which produce a comprehensive array of goods and services. The Company's operations are subject to various foreign, federal, state and local safety laws.
» More Articles for PKI

Headlines

Articles On GuruFocus.com
Parkland Fuel Corporation Announces October 2014 Dividend Oct 15 2014 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
The Best Dividends on April 18, 2012 Apr 18 2012 
PerkinElmer Inc. Reports Operating Results (10-K) Mar 01 2011 
PerkinElmer Inc. Reports Operating Results (10-Q) Nov 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) May 13 2010 
PerkinElmer Inc. (PKI) Chairman, President & CEO Robert F Friel sells 150,000 Shares Dec 17 2009 
PerkinElmer Acquires Leading Diagnostics Company in China Sep 08 2009 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 14 2009 


More From Other Websites
PerkinElmer Completes Acquisition of Perten Instruments Dec 15 2014
Global Mammography Market is Projected to be $2.8 Billion by 2020 Dec 11 2014
PerkinElmer, UCLA and OncoSec Collaborate to Evaluate Patient-Selection Biomarker in Immunotherapy Dec 02 2014
OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate... Dec 02 2014
PERKINELMER INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Nov 28 2014
PerkinElmer Inks $266M Deal to Buy Perten Instruments Nov 25 2014
New exit: Valedo divests Perten Instruments to PerkinElmer Inc. Nov 24 2014
PerkinElmer Enters into Definitive Agreement to Acquire Perten Instruments Nov 24 2014
PerkinElmer to Present at Piper Jaffray Healthcare Conference Nov 19 2014
PERKINELMER INC Financials Nov 11 2014
PerkinElmer to Present at Jefferies 2014 Global Healthcare Conference Nov 10 2014
PerkinElmer to Present at Jefferies 2014 Global Healthcare Conference Nov 10 2014
10-Q for PerkinElmer, Inc. (United States) Nov 06 2014
PERKINELMER INC Files SEC form 10-Q, Quarterly Report Nov 04 2014
PerkinElmer (PKI) Earnings Report: Q3 2014 Conference Call Transcript Oct 31 2014
PerkinElmer (PKI) Posts In-Line Q3 Earnings, Revenue Miss Oct 31 2014
PerkinElmer Announces Financial Results for the Third Quarter of 2014 Oct 30 2014
PerkinElmer Inc Earnings Call scheduled for 5:00 pm ET today Oct 30 2014
PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 30 2014
PerkinElmer meets 3Q profit forecasts Oct 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK